2m 2m 2m 2m 2m 2m 2m
MBX BIO (MBX)
NASDAQ
$30.05-$0.65 (-2.13%)
Price as of Jun 03, 2026 4:35 PM EDT- $1.5BMarket Cap
- 124.74%1-Year Change
- BiotechnologyIndustry
MBX BIO (MBX)
$30.05-$0.65 (-2.13%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -79.2M +37.87% | -57.4M N/A | |
Depreciation and Amortization Expense | 248,000 +1.64% | 244,000 N/A | |
Total Operating Expenses | 98.1M +43.79% | 68.2M N/A | |
Operating Profit | -98.1M +43.79% | -68.2M N/A | |
Interest Income | 11.1M +76.72% | 6.3M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 11.1M +76.72% | 6.3M N/A | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | |
Income before Taxes | -87.0M +40.45% | -61.9M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -87.0M +40.45% | -61.9M N/A | |
Net Income from Continuing Operations Applicable to Common | -87.0M +40.45% | -61.9M N/A | |
Basic EPS and Net Income | -2.38 -59.11% | -5.82 N/A | |
Diluted EPS and Net Income | -2.38 -59.11% | -5.82 N/A | |
Basic Weighted Average Shares | 36.5M +243.01% | 10.6M N/A | |
Diluted Weighted Average Shares | 36.5M +243.01% | 10.6M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 75.3M +52.56% | 49.4M N/A | |
Short-Term Investments | 298.4M +40.23% | 212.8M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 373.7M +42.55% | 262.1M N/A | |
Total Current Assets | 381.5M +42.75% | 267.3M N/A | |
Accumulated Depreciation | 670,000 +58.77% | 422,000 N/A | |
Property and Plant and Equipment and Net | 2.7M +153.24% | 1.1M N/A | |
Total Long-Term Assets | 383,000 +666.00% | 50,000 N/A | |
Total Assets | 385.1M +43.42% | 268.5M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 15.5M +40.21% | 11.1M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 424,000 N/A | 0 N/A | |
Total Liabilities | 15.9M +43.52% | 11.1M N/A | |
Retained Earnings | -224.5M +63.25% | -137.5M N/A | |
Total Stockholders Equity | 369.2M +43.42% | 257.4M N/A | |
Total Shares Outstanding | 44.9M +34.43% | 33.4M N/A | |
Cash Flow | |||
Cash from Operating Activities | -79.9M +46.21% | -54.7M N/A | |
Capital Expenditures | 1.9M +120.71% | 874,000 N/A | |
Cash from Investing Activities | -83.7M -47.88% | -160.6M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 189.6M -19.01% | 234.1M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -26.61% N/A | N/A N/A | |
Return on Equity | -27.76% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 24.62 N/A | N/A N/A | |
Cash Ratio | 4.86 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow